Knee replacement sales outside the U.S. became an important growth driver for the largest orthopedic companies as procedure volumes recovered and robotics gained acceptance in international markets.
Our chart of the month shows the combined knee replacement and hip replacement sales for Zimmer Biomet, Stryker and Johnson & Johnson MedTech from 2016 to 2024. These three companies account for more than 63% of global joint replacement sales.
Knee replacement sales outside the U.S. are the fastest-growing segment of the four presented in the chart, with notable strength over the last two years during which it averaged double-digit growth. The emergence of joint replacement robots in OUS markets helped these companies increase their global footprint.
“The hip and knee growth we’re seeing internationally will be a gift that keeps giving for the next few years. We’re hitting our stride and feeling very bullish about the future,” said Stryker CEO Kevin Lobo.
Hip replacement sales within the U.S. have been improved in recent years, growing in the upper mid-single-digits since 2020. However, hip sales outside the U.S. remain challenged, with a CAGR of just 1.5% from 2016 to 2024 for our three companies in the chart.
We expect joint replacement growth rates to further moderate in 2025, but remain slightly above historical norms. We also expect these orthopedic companies and more to increase investment in OUS opportunities.
Knee replacement sales outside the U.S. became an important growth driver for the largest orthopedic companies as procedure volumes recovered and robotics gained acceptance in international markets.
Our chart of the month shows the combined knee replacement and hip replacement sales for Zimmer Biomet, Stryker and Johnson & Johnson MedTech...
Knee replacement sales outside the U.S. became an important growth driver for the largest orthopedic companies as procedure volumes recovered and robotics gained acceptance in international markets.
Our chart of the month shows the combined knee replacement and hip replacement sales for Zimmer Biomet, Stryker and Johnson & Johnson MedTech from 2016 to 2024. These three companies account for more than 63% of global joint replacement sales.
Knee replacement sales outside the U.S. are the fastest-growing segment of the four presented in the chart, with notable strength over the last two years during which it averaged double-digit growth. The emergence of joint replacement robots in OUS markets helped these companies increase their global footprint.
“The hip and knee growth we’re seeing internationally will be a gift that keeps giving for the next few years. We’re hitting our stride and feeling very bullish about the future,” said Stryker CEO Kevin Lobo.
Hip replacement sales within the U.S. have been improved in recent years, growing in the upper mid-single-digits since 2020. However, hip sales outside the U.S. remain challenged, with a CAGR of just 1.5% from 2016 to 2024 for our three companies in the chart.
We expect joint replacement growth rates to further moderate in 2025, but remain slightly above historical norms. We also expect these orthopedic companies and more to increase investment in OUS opportunities.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
